What's Happening?
Karyopharm Therapeutics Inc. announced the topline results from its Phase 3 XPORT-EC-042 trial, which evaluated selinexor as a maintenance therapy for TP53 wild-type advanced or recurrent endometrial cancer. The trial did not meet its primary endpoint
of progression-free survival, although a trend favoring selinexor was observed, with a median progression-free survival of 12.75 months compared to 7.43 months for the placebo. The safety profile of selinexor was consistent with previous findings, with no new safety signals. Despite the trial's outcome, Karyopharm plans to continue following patients for longer-term outcomes and will present the data at a future medical meeting.
Why It's Important?
The trial results are significant for the field of oncology, particularly for patients with endometrial cancer, who have limited maintenance therapy options. While the primary endpoint was not met, the observed trend suggests potential benefits of selinexor, warranting further investigation. The findings contribute to the scientific understanding of XPO1 inhibition in cancer treatment. Karyopharm's decision to prioritize resources on its myelofibrosis and multiple myeloma programs indicates a strategic shift, potentially impacting its research and development focus and financial allocation.
What's Next?
Karyopharm will conduct a full evaluation of the trial data and plans to present the findings at an upcoming medical meeting. The company remains committed to exploring selinexor's potential in other cancer indications, including myelofibrosis and multiple myeloma. Future milestones include the submission of a supplemental New Drug Application (sNDA) and the release of topline data from ongoing trials. The company's strategic focus on myelofibrosis and multiple myeloma may lead to new treatment options and market opportunities.
